share_log

Intelligent Bio Solutions | 8-K: Intelligent Bio Solutions Inc. Announces Preliminary Unaudited Fiscal Third Quarter and Nine-Month Revenue Results

Intelligent Bio Solutions | 8-K: Intelligent Bio Solutions Inc. Announces Preliminary Unaudited Fiscal Third Quarter and Nine-Month Revenue Results

Intelligent Bio Solutions | 8-K:Intelligent Bio Solutions Inc. 公佈未經審計的第三財季初步收入和九個月收入業績
美股sec公告 ·  04/18 16:33
Moomoo AI 已提取核心訊息
Intelligent Bio Solutions Inc. reported a significant increase in preliminary unaudited revenue for both the fiscal third quarter and the nine months ending March 31, 2024. The company, which specializes in non-invasive drug testing technology, announced an 80% revenue increase for the quarter and a 193% increase for the nine-month period compared to the previous year. These results were driven by record cartridge sales since the acquisition of Intelligent Fingerprinting Limited in 2022. Cartridge sales rose by 17% and reader sales by 20% for the quarter, with a 25% and 63% increase, respectively, from July 1, 2023, to March 31, 2024. President and CEO Harry Simeonidis attributed the growth to the market's recognition of the need for comprehensive drug testing solutions in response to the rise of synthetic drugs. The company expects to release its full financial results for the quarter and nine-month period in its upcoming Quarterly Report on Form 10-Q, to be filed with the SEC in early May 2024.
Intelligent Bio Solutions Inc. reported a significant increase in preliminary unaudited revenue for both the fiscal third quarter and the nine months ending March 31, 2024. The company, which specializes in non-invasive drug testing technology, announced an 80% revenue increase for the quarter and a 193% increase for the nine-month period compared to the previous year. These results were driven by record cartridge sales since the acquisition of Intelligent Fingerprinting Limited in 2022. Cartridge sales rose by 17% and reader sales by 20% for the quarter, with a 25% and 63% increase, respectively, from July 1, 2023, to March 31, 2024. President and CEO Harry Simeonidis attributed the growth to the market's recognition of the need for comprehensive drug testing solutions in response to the rise of synthetic drugs. The company expects to release its full financial results for the quarter and nine-month period in its upcoming Quarterly Report on Form 10-Q, to be filed with the SEC in early May 2024.
Intelligent Bio Solutions Inc.報告稱,第三財季和截至2024年3月31日的九個月未經審計的初步收入均大幅增加。該公司專門從事非侵入性藥物測試技術,宣佈與去年同期相比,本季度收入增長80%,九個月期間增長193%。這些業績是由自2022年收購智能指紋有限公司以來的唱片盒銷售推動的。從2023年7月1日至2024年3月31日,本季度墨盒銷量增長了17%,閱讀器銷量增長了20%,分別增長了25%和63%。總裁兼首席執行官哈里·西蒙尼迪斯將增長歸因於市場認識到需要全面的藥物測試解決方案來應對合成藥物的興起。該公司預計將在2024年5月初向美國證券交易委員會提交的即將發佈的10-Q表季度報告中發佈本季度和九個月期間的完整財務業績。
Intelligent Bio Solutions Inc.報告稱,第三財季和截至2024年3月31日的九個月未經審計的初步收入均大幅增加。該公司專門從事非侵入性藥物測試技術,宣佈與去年同期相比,本季度收入增長80%,九個月期間增長193%。這些業績是由自2022年收購智能指紋有限公司以來的唱片盒銷售推動的。從2023年7月1日至2024年3月31日,本季度墨盒銷量增長了17%,閱讀器銷量增長了20%,分別增長了25%和63%。總裁兼首席執行官哈里·西蒙尼迪斯將增長歸因於市場認識到需要全面的藥物測試解決方案來應對合成藥物的興起。該公司預計將在2024年5月初向美國證券交易委員會提交的即將發佈的10-Q表季度報告中發佈本季度和九個月期間的完整財務業績。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息